#USA #Barcelona #Congruence Therapeutics #CGX-195 #AAT Deficiency

Congruence Therapeutics Presents CGX-195 at ERS Alpha-1 Antitrypsin Conference 2026

On October 23, 2026, Congruence Therapeutics, a leading clinical-stage biotechnology firm, announced its participation in the European Respiratory Society (ERS) Alpha-1 Antitrypsin Conference in Barcelona, Spain. During this highly anticipated event, the company will present their oral findings on CGX-195, a promising oral treatment for Alpha-1 Antitrypsin Deficiency (AATD).

Overview of CGX-195

CGX-195, also known as CO-8195, is an innovative small molecule developed to address the underlying issues associated with AATD by correcting misfolded proteins. The therapy shows great promise by effectively increasing functional, secreted Z-A1AT levels while decreasing the polymerized form of Z-A1AT. This is particularly significant as these polymerized variants can lead to severe lung and liver complications, including emphysema and cirrhosis.

Presentation Details

The oral presentation will be delivered by Anzhelika Kabro, Senior Director of Chemistry at Congruence Therapeutics, on Friday, October 23, 2026, from 16:50 to 17:00 CEST. Participants attending the conference can look forward to insights regarding the efficacy of CGX-195 based on preclinical studies conducted both in cellular assays and the PiZ mouse model, which simulates challenges faced in AATD.

Importance of the Findings

Congruence's Chief Scientific Officer, Dr. Sharath Hegde, expressed excitement over the opportunity to share these pivotal results at a key scientific meeting. CGX-195's ability to rectify the misfolding of the Z variant could lead to crucial advancements in treating both lung and liver manifestations of the disease. Unlike existing treatments that require regular intravenous administration, CGX-195 presents itself as a potential oral solution, thus improving patient compliance and accessibility.

The findings are especially heartening for the 1 in 2,500 people globally affected by AAT deficiency—a genetic disorder resulting from mutations in the SERPINA1 gene, which leads to a deficiency of the A1AT protein. When functioning correctly, A1AT plays a protective role in the lungs, and this deficiency leaves patients vulnerable to serious damage from proteases, contributing to respiratory diseases such as early-onset emphysema and chronic obstructive pulmonary disease (COPD).

CGX-195 Development Journey

The technology behind CGX-195 stems from Congruence’s state-of-the-art Revenir™ computational platform. This platform enables researchers to model protein structures at the atomic level, facilitating the identification of molecules capable of rectifying protein misfolding. As Congruence moves forward, they are keenly focused on completing the necessary IND-enabling activities, aiming for a clinical trial launch in 2027.

In addressing the dual challenges of treating respiratory and liver manifestations of AATD, CGX-195 exemplifies a shift towards innovative therapeutic strategies that focus on correcting the root causes of genetic disorders rather than merely managing symptoms. Such advancements could revolutionize how AATD is approached in clinical settings, providing hope for better patient outcomes, and potentially transforming the landscape of genetic therapies.